Phylogenetic identification of bacterial MazF toxin protein motifs among probiotic strains and foodborne pathogens and potential implications of engineered probiotic intervention in food by Xianghe Yan et al.
Cell & Bioscience
Yan et al. Cell & Bioscience 2012, 2:39
http://www.cellandbioscience.com/content/2/1/39RESEARCH Open AccessPhylogenetic identification of bacterial MazF toxin
protein motifs among probiotic strains and
foodborne pathogens and potential implications
of engineered probiotic intervention in food
Xianghe Yan1*, Joshua B Gurtler1, Pina M Fratamico1, Jing Hu2 and Vijay K Juneja1Abstract
Background: Toxin-antitoxin (TA) systems are commonly found in bacteria and Archaea, and it is the most
common mechanism involved in bacterial programmed cell death or apoptosis. Recently, MazF, the toxin
component of the toxin-antitoxin module, has been categorized as an endoribonuclease, or it may have a function
similar to that of a RNA interference enzyme.
Results: In this paper, with comparative data and phylogenetic analyses, we are able to identify several potential
MazF-conserved motifs in limited subsets of foodborne pathogens and probiotic strains and further provide a
molecular basis for the development of engineered/synthetic probiotic strains for the mitigation of foodborne
illnesses. Our findings also show that some probiotic strains, as fit as many bacterial foodborne pathogens, can be
genetically categorized into three major groups based on phylogenetic analysis of MazF. In each group, potential
functional motifs are conserved in phylogenetically distant species, including foodborne pathogens and probiotic
strains.
Conclusion: These data provide important knowledge for the identification and computational prediction of
functional motifs related to programmed cell death. Potential implications of these findings include the use of
engineered probiotic interventions in food or use of a natural probiotic cocktail with specificity for controlling
targeted foodborne pathogens.
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Foodborne illnesses continue to be an important public
health concern in developing, as well as in developed
countries, thus prevention of foodborne illness outbreaks
through effective and novel interventions should be
given priority. The U.S. Public Health Service has identi-
fied ten important foodborne pathogens causing human
illnesses, including pathogenic strains of Escherichia coli,
Salmonella, Listeria, Clostridium botulinum, Shigella,
and Campylobacter, which are associated with more
than 250 known foodborne diseases (http://www3.niaid.
nih.gov/topics/foodborne/default.htm).* Correspondence: xianghe.yan@ars.usda.gov
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reproduction in any medium, provided the orIn addition, according to the World Health Or-
ganization (WHO), antibiotic overuse in food animal
production is a major contributor to the emergence of
antibiotic resistant foodborne pathogens [1]. The use of
antibiotics in food animals for growth promotion and
treatment disrupts the normal beneficial commensal
bacterial microflora in the animal intestinal tract [2-6].
Recently, the human and chicken gut microbiome pro-
jects [7-12] have shed new light on the existence of a
bacterial ‘phylogenetic core’ [13] consisting of a wide di-
versity of gastrointestinal bacteria by using new tech-
nologies such as next generation sequencing, 16S rRNA
screens, metagenomics, and metaproteomics. Healthful,
commensal bacteria found in the GI tract might be key
members of known or potential probiotic strains
revealed in this ‘phylogenetic core’, which may include. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ilus, Lactobacillus reuteri, Lactobacillus rhamnosus GG
(ATCC 53103), Bifidobacterium infantis, Saccharomyces
boulardii, Lactobacillus ruminis, Lactobacillus johnsonii
str. NCC 533, and many others. These known probiotic
strains have been used as dietary supplements, as treat-
ments for illnesses caused by foodborne pathogens, and
for disease prevention. Use of probiotic strains not only
reduce invasion by bacterial pathogens, but also restore
and maintain an optimal balance of healthy commensal
bacteria in the human gut via production of antimicro-
bials [14-23].
One of the major mechanisms recognized as being re-
sponsible for apoptosis, or programmed cell death, and
production of toxic metabolites in bacteria is through
the regulation of a wide variety of bacterial toxin-
antitoxin modules [24-26], such as MazE/MazF, a
chromosomal toxin-antitoxin module [27-30], plasmid-
encoded parD [31-33], chpBIK [26,34], relBE [35,36],
and the PhoQ-PhoP system [37-40]. MazEF is one of the
most well-studied toxin–antitoxin (TA) systems and has
been found on the chromosomes of many bacteria. The
MazF protein has been recently categorized as an endor-
ibonuclease [41,42] or as a type of RNA interference en-
zyme [43]. The link between this TA system and
quorum sensing has also been explored recently through
a small pentapeptide (NNWNN) called the Extracellular
Death Factor (EDF) [44]. This small peptide motif (such
as NNWNN) is known to be an extra-cellular death fac-
tor in E. coli and other bacterial species. The necessity of
an “extracellular death factor” (EDF) or “cell death fac-
tor” (CDF) via MazEF-mediated cell death is a popula-
tion phenomenon requiring the activation of quorum-
sensing (cell-to-cell signaling) peptides in bacteria. High
cell density was found to be associated with elevated
concentrations of EDF, and the presence of EDF resulted
in MazF-induced cell death [44]. From a food safety and
public health perspective, use of EDF or a similar strat-
egy may be used in place of antibiotics, resulting in less
usage of antibiotics. We also noticed in one very inter-
esting study that the induction of toxin MazF and the
use of antibiotic share a similar mechanism by inhibiting
the transcription and/or translation of the MazE anti-
toxin [45].
It has been theorized that there is “one toxin for one
antitoxin” and interestingly MazF, in some bacteria,
exhibits a selective inhibition of ribosomes and mRNAs
[43,46]. Numerous strains of probiotic bacteria, such as
Lactobacillus spp., have been reported to produce anti-
microbial agents [47], such as bacteriocins, that inhibit
or kill closely-related species, or even different strains of
the same species through the inhibition of transcription
and translation by receptor binding. The antimicrobial
activities of bacteriocins are due to a heterologoussubgroup of ribosomally synthesized cationic peptides
[48]. Nisin, a polycyclic antibacterial peptide 34 amino
acid residues long, is one of the most studied bacteriocins
and is produced by many strains of Lactococcus lactis. It
has been approved by the FDA for use as a food preser-
vative, and certain probiotic Lactobacillus strains have
been thoroughly studied and evaluated in vitro and
in vivo. For example, L. reuteri controls diarrhea in chil-
dren and suppresses the growth and pathogenicity of
harmful foodborne pathogens such as Salmonella, E. coli,
Staphylococcus, and Listeria [49,50]. L. casei GG has been
used to treat Clostridium difficile infections and to reduce
intestinal permeability [51-54]. L. reuteri is known to
produce a broad-spectrum antimicrobial agent, reuterin,
composed of the natural metabolic compound 3-hydro-
xypropionaldehyde, which has been used on the surface
of sausages to inhibit growth of harmful bacteria and fungi
[15,16]. However, the molecular mechanisms underlying
the effectiveness of individual probiotic strains have not
been systematically studied and characterized. Several po-
tential mechanisms of action, including their ability to
generate diverse natural toxic metabolites, lactic acid, and
other organic acids, enzymes, vitamins, and hydrogen per-
oxide, as well as antimicrobial peptides such as nisin, have
been well-described [20].
The work reported herein explores the experimental
antimicrobial possibilities and/or procedures for (1) ex-
pression of an engineered, stress-induced recombinant
secreted fusion gene encoded by MazF and a small
extracellular cell death factor (CDF) on the surface or
extracellular space of recombinant probiotic bacteria or
(2) for potential application of a cocktail of natural pro-
biotic strains via experimental in vitro selection to con-
trol foodborne pathogens for improving the safety and
quality of foods, as well as improving human health. The
use of engineered probiotic strains or the natural pro-
biotic cocktail consisting of mixed probiotic strain popu-
lations for targeting foodborne pathogens will potentially
be able to selectively inactivate these pathogens, even in
complex food matrices. Through gene/motif reshuffling
[55,56] and computational molecular modeling, this
engineered and secreted bacterial fusion protein, MazF-
CDF, which contains an enterokinase (EK) cleavage site
[57-60] for releasing active CDF and MazF after protein
secretion, should have a narrow range of applicability,
limited to inactivating only specific foodborne pathogens
such as E. coli O157, Salmonella, Listeria, Campylobac-
ter, and potentially other human pathogens. This patho-
gen specificity is due to the fact that the genetically-
engineered MazF-CDF fusion protein could be modified
by the inclusion of specific genomic DNA sequences
from various commensal, as well as pathogenic bacterial
strains, identified through DNA/protein structure and
functional comparisons. Additionally, this engineered
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beneficial (healthful/probiotic) bacteria, as well as to its
host that expresses the protein/peptide. Moreover, these
engineered and secreted CDFs and MazF proteins/pep-
tides can easily pass through infectious foodborne patho-
gen cell barriers mediating cell death, and thus could
potentially reduce the use of deleterious compounds
such as antibiotics or other harmful chemicals in the
feed and food industry.
Results and discussion
General genetic analysis of probiotics and foodborne
pathogen genomes
The genomic information from selected probiotic strains
and foodborne pathogens is shown in Table 1. It
revealed little diversity in genomic GC-content in the
Bifidobacterium genus, while showing an astonishing di-
versity in the GC-content among Lactobacillus species,
ranging from 33 to 51.5%. It has been demonstrated that
genomic GC-content is correlated with a number of fac-
tors [61], including genome size [62] from species such
as Lactobacillus, which ranges from 1.8 to 3.4 Mb in
length. This demonstrates that the GC-content and gen-
ome size of Lactobacillus genomes may have implica-
tions related to the biological complexity and adaptation
of this genus, and could be due to the rate of recombin-
ation that has been extensively studied in the E. coli gen-
ome [63]. Knowledge of genetic diversity is fundamental
to development of synthetic probiotic genomes and/or
nucleic acid sequence reshuffling strategies. In this
paper, we demonstrate that the MazF protein is a suit-
able candidate for the determination of genetic relation-
ships within sets of MazF proteins in combination with
with functional motif analysis.
Ubiquitous existence of MazE/toxin, MazF
MazEF is a toxin-antitoxin (TA) module widely distribu-
ted among many bacterial species, including both food-
borne pathogens and probiotic strains (Table 1, 2), such
as Lactobacillus acidophilus, Lactobacillus reuteri, Lacto-
bacillus rhamnosus GG (ATCC 53103), Escherichia coli,
Selenomonas sputigena, Enterobacter spp., Campylobac-
ter spp., Citrobacter spp., Thermoanaerobacter tengcon-
gensis, Pelotomaculum thermopropionicum, Lactobacillus
casei, Lactobacillus crispatus, Lactobacillus buchneri,
Bifidobacterium longum subsp. infantis, Clostridium
botulinum, Clostridium difficile, Vibrio spp., Listeria
spp., Bacillus spp., Klebsiella variicola, and Salmonella
enterica. Recent literature and computational analyses
have shown the presence of many different types of TA
modules in various localizations, e.g. some TA modules
have been found within prophages, prophage-like ele-
ments, and other mobile genetic elements, such as plas-
mids [31-33]. Due to the existence of varying types oftoxin-antitoxin modules and possible gene duplication
events, in this paper we present the above one-to-one
best matches of chromosomal-encoded mazF orthologs
and homologs among 75 publically available genome
sequences of foodborne pathogens and probiotic strains
(Table 1), and the publically-available databases such as
NCBI and the Uniprot database (http://www.uniprot.
org/) in Table 2.
Phylogenetic analyses and cluster analysis of MazF/
antitoxin protein, a growth inhibitor
The phylogenetic tree in Figure 1 displays the phylogen-
tic relationships of many well-recognized genera within
Enterobacteriaceae, including several important food-
borne pathogens such as pathogenic E. coli, Salmonella,
Listeria, and Campylobacter, as well as some major pro-
biotic strains. To build a phylogenetic tree from the data
in Table 2, the amino acid sequences of all the MazF or
growth inhibitor proteins were analyzed using the Gen-
eious software package v5.5.7 with Neighbor-joining
(NJ) method by applying ClustalW for sequence align-
ment (Figure 1). Three main clusters (viz., groups 1, 2,
and 3) are given in Figure 1. At least two representatives
of potential probiotic strains are listed for each group,
depending on the complexity of groups. In group 1, the
potential probiotic, non-pathogenic strains, such as
Lactobacillus amylovorus, Lactobacillus crispatus,
Streptococcus, Enterococcus faecium, Enterococcus, Lacto-
bacillus plantarum, and Lactobacillus rhamnosus, are
grouped with the foodborne pathogens E. coli, Vibrio
vulnificus, and Vibrio cholerae. In group 2, the food-
borne pathogens Enterobacter, Campylobacter upsalien-
sis, Klebsiella variicola, Salmonella enterica, Shigella
flexneri, Shigella dysenteriae, and Citrobacter rodentium
were shown to be genetically closer to Bacillus selenitire-
ducens, Bacillus halodurans, and Enterococcus faecalis
In group 3, some probiotic strains, such as the Bacillus,
Lactobacillus, Leuconostoc, and the Bifidobacterium gen-
era are categorized along with other major foodborne
pathogens, such as Clostridium difficile, Listeria monocy-
togenes, Listeria grayi, and an emerging foodborne
pathogen Pediococcus pentosaceus.
Phylogenetic identification of bacterial toxin MazF
protein motifs and the relationship between gene
structure and phylogenetic classification
In Figure 2, it is shown that the number of candidate
motifs are slightly different in each group, but with a
high degree of amino acid sequence variability within
conserved “hot spots” between groups 1, 2, and 3. To
determine which motifs are the best candidates for the
engineered MazF construction (discussed in next sec-
tion) in each individual group, recent studies [43] sug-
gest that the N-terminal (the first 80 amino acids in
Table 1 Genomic information of selected microorganisms considered as potential probiotic strains and some major










Campylobacter upsaliensis JV21 pathogenic ASM18534v1 NA 1.6
Lactobacillus coleohominis 101-4-CHN probiotic ASM16193v1 41.3 1.7
Campylobacter jejuni RM1221 pathogenic NC_003912.7 30.3 1.8
Lactobacillus johnsonii FI9785 probiotic NC_013504.1 34.4 1.8
Pediococcus pentosaceus ATCC 25745 probiotic CP000422.1 37.4 1.8
Streptococcus thermophilus LMG LMG 18311 probiotic NC_006448.1 39.1 1.8
Lactobacillus gasseri ATCC 33323 probiotic NC_008530.1 35.3 1.9
Lactobacillus sakei subsp. sakei 23K probiotic NC_007576.1 41.3 1.9
Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 probiotic NC_008054.1 49.7 1.9
Lactobacillus delbrueckii subsp. bulgaricus ATCC BAA-365 probiotic NC_008529.1 49.7 1.9
Leuconostoc citreum KM20 probiotic ASM2640v1 38.9 1.9
Bifidobacterium animalis subsp. Lactis Bl-04 probiotic NC_012814.1 60.5 1.9
Bifidobacterium animalis subsp. Lactis DSM 10140 probiotic NC_012815.1 60.5 1.9
Bifidobacterium animalis subsp. Lactis AD011 probiotic NC_011835.1 60.5 1.9
Lactobacillus amylovorus GRL1118 probiotics ASM19411v1 38.0 2.0
Lactobacillus johnsonii NCC 533 probiotic NC_005362.1 34.6 2.0
Lactobacillus acidophilus NCFM probiotic NC_006814.3 34.7 2.0
Lactobacillus reuteri DSM 20016 probiotic NC_009513.1 38.9 2.0
Lactobacillus reuteri JCM 1112 probiotic NC_010609.1 38.9 2.0
Listeria monocytogenes FSL J1-208 pathogenic ASM16843v1 37.7 2.0
Lactobacillus salivarius UCC118 probiotic NC_007929.1 33 2.1
Lactobacillus helveticus DPC 4571 probiotic NC_010080.1 37.1 2.1
Leuconostoc mesenteroides subsp. mesenteroides ATCC 8293 probiotic NC_008531.1 37.7 2.1
Campylobacter concisus 13826 pathogenic NC_009802.1 39.3 2.1
Lactobacillus fermentum IFO 3956 probiotic NC_010610.1 51.5 2.1
Bifidobacterium adolescentis ATCC 15703 probiotic NC_008618.1 59.2 2.1
Bifidobacterium bifidum PRL2010 probiotic NC_014638.1 Na 2.2
Bifidobacterium bifidum S17 probiotic NC_014616.1 Na 2.2
Lactobacillus amylovorus GRL 1112 probiotic NC_014724.1 Na 2.2
Lactobacillus brevis ATCC 367 probiotic NC_008497.1 46.1 2.3
Lactobacillus crispatus CTV-05 probiotic ASM16588v1 37.1 2.3
Bifidobacterium longum NCC2705 probiotic NC_004307.2 60.1 2.3
Bifidobacterium longum subsp. longum BBMN68 probiotic NC_014656.1 Na 2.3
Bifidobacterium longum subsp. infantis 157F probiotic NC_015052.1 Na 2.4
Bifidobacterium longum subsp. longum JCM 1217 probiotic NC_015067.1 Na 2.4
Lactococcus lactis subsp. lactis Il1403 probiotic NC_002662.1 35.3 2.4
Bifidobacterium longum DJO10A probiotic NC_010816.1 60.2 2.4
Bifidobacterium longum subsp. longum JDM301 probiotic NC_014169.1 Na 2.5
Lactococcus lactis subsp. cremoris MG1363 probiotic NC_009004.1 35.7 2.5
Listeria grayi DSM 20601 pathogenic ASM14899v1* 41.6 2.6
Propionibacterium freudenreichii subsp. shermanii CIRM-BIA1 probiotic NC_014215.1 Na 2.6
Lactococcus lactis subsp. lactis KF147 probiotic NC_013656.1 34.9 2.6
Lactococcus lactis subsp. cremoris SK11 probiotic NC_008527.1 35.8 2.6
Bifidobacterium dentium Bd1 probiotic NC_013714.1 58.5 2.6
Bifidobacterium longum subsp. infantis ATCC 15697 probiotic NC_011593.1 59.9 2.8
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Table 1 Genomic information of selected microorganisms considered as potential probiotic strains and some major
food-borne pathogens used in this study (Continued)
Listeria monocytogenes EGD-e pathogenic NC_003210.1 38 2.9
Lactobacillus casei str. Zhang probiotic NC_014334.1 40.1 2.9
Lactobacillus casei ATCC 334 probiotic NC_008526.1 46.6 2.9
Lactobacillus paracasei subsp. paracasei ATCC 25302 probiotic ASM15949v1 46.5 2.9
Lactobacillus rhamnosus GG probiotic NC_013198.1 46.7 3.0
Lactobacillus rhamnosus Lc 705 probiotic NC_013199.1 46.7 3.0
Lactobacillus casei BL23 probiotic NC_010999.1 46.3 3.1
Lactobacillus plantarum JDM1 probiotic NC_012984.1 44.7 3.2
Enterococcus faecalis V583 probiotic NC_004668.1 37.4 3.3
Lactobacillus plantarum WCFS1 probiotic NC_004567.1 44.4 3.3
Lactobacillus plantarum subsp. plantarum ST-III probiotic NC_014554.1 Na 3.4
Bacillus selenitireducens MLS10 Bio agent ASM9308v1 48.7 3.6
Bacillus pumilus SAFR-032 probiotic NC_009848.1 41.3 3.7
Coprobacillus sp. 29_1 Non-pathogenic Coprobacillus_sp_29_1_V1 NA 3.8
Vibrio cholerae M66-2 pathogenic NC_012578.1 47.6 3.9
Bacillus halodurans C-125 Non-pathogenic ASM1114v1 43.7 4.2
Bacillus amyloliquefaciens Y2 probiotic ASM28439v1 45.9 4.2
Clostridium difficile 630 pathogenic NC_009089.1 29.1 4.3
Bacillus clausii KSM-K16 probiotic NC_006582.1 44.8 4.3
Shigella dysenteriae Sd197 pathogenic ASM1200v1] 50.9 4.6
Shigella flexneri 8401 pathogenic NC_008258.1 50.9 4.6
Salmonella enterica subsp. arizonae serovar RSK2980 pathogenic NC_010067.1 51.4 4.6
Enterobacter sp. 638 pathogenic NC_009436.1 52.9 4.7
Vibrio vulnificus CMCP6 pathogenic NC_004459.2 46.7 5.1
Escherichia coli E24377A pathogenic NC_009801.1 50.6 5.2
Citrobacter rodentium ICC168 pathogenic NC_013716.1 54.6 5.4
Klebsiella variicola At-22 pathogenic NC_013850.1 57.6 5.5
Bacillus megaterium QM B1551 probiotic ASM2582v1 38.0 5.5
Escherichia coli O157:H7 Sakai pathogenic NC_002695.1 50.5 5.6
Bacillus thuringiensis serovar israelensis ATCC 35646 Bio agents ASM16769v1 35.0 5.9
Lachnospiraceae bacterium 3_1_57FAA_CT1 Non-pathogenic Lach_bact_3_1_57FAA_CT1_V1 NA 7.7
*: assembly accession.
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motifs. The other motifs in the C-terminal might be re-
ferred to as ‘incorrect’ motifs. There are three criteria
for evaluating the remaining motifs as “incorrect and
without biological significance”, and this is related to:
the mean hydrophobicity, identity, and the gene struc-
ture. In Figure 2, in the analysis for the phylogenetic
identification of bacterial Toxin MazF protein motifs,
the mean hydrophobicity sequence and identity were
computed and compared for each sequence; it is inter-
esting to find that all the compared MazF proteins have
a higher degree of mean hydrophobicity, identity, and
more conserved gene structure among several conserved
amino acid regions, particular in the N-terminal. The se-
lection of potential functional MazF motifs is discussed
in the next section. The functional importance of themean hydrophobicity has also been discussed to involve
mRNA and protein degradation and slower translation
of mRNA for disordered proteins (http://employees.
csbsju.edu/hjakubowski/classes/ch331/protstructure/
olprotfold.html).
Bacterial probiotic cocktail strains
It is important to note that the benefits of probiotics are
strain-specific [64,65]. A commercial product, VSL#3,
developed by Sigma-Tau Pharmaceuticals, Inc., provides
a mixture of probiotic bacteria (B. breve, B. infantis, B.
longum, L. acidophilus, L. bulgaricus, L. casei, L. plan-
tarum, and Streptococcus thermophilus) to help protect
GI tract integrity [66]. In this study, the bacterial pro-
biotic cocktail strains we propose would be comprised
of all representatives of groups 1, 2, and 3 shown in
Table 2 The genetic characterization of the transcriptional modulator MazF, a chromosomal cell death factor from











Enterobacter sp. pathogen 638 ABP60743.1* transcriptional modulator of
MazE/toxin, MazF
Shigella dysenteriae pathogen Sd197 YP_405833.1* toxin ChpB
Citrobacter rodentium pathogen ICC168 YP_003366767.1* Toxin component of the ChpB-ChpS
toxin-antitoxin system
Vibrio vulnificus pathogen CECT4999=R99 YP_001393091.1* growth inhibitor
Listeria welshimeri serovar 6b str. pathogen SLCC5334 YP_849071.1 PemK family transcriptional regulator
FSL J1-208 ZP_05296226.1* PemK family transcriptional regulator
Listeria monocytogenes SLCC3954 YP_003464028.1 transcriptional regulator, PemK family
FSL S4-120 ZP_07870171.1 toxin-antitoxin system, antitoxin
component, MazF family
Listeria seeligeri serovar 1/2b str.
Listeria marthii
Listeria grayi pathogen DSM 20601 ZP_07054243.1* MazF family toxin-antitoxin system protein
Clostridium difficile pathogen 630 YP_001089981.1* putative regulator of cell growth
QCD-66c26 ZP_05273557.1 putative regulator of cell growth
CIP 107932 ZP_05323891.1 putative regulator of cell growth
Klebsiella variicola pathogen At-22 YP_003438577.1* transcriptional modulator of MazE/toxin,
MazF pemK; protein PemK1_1_55 ZP_06548086.1
Salmonella enterica subsp.
arizonae serovar
pathogen RSK2980 YP_001573441.1* hypothetical protein SARI_04525
Campylobacter showae pathogen RM3277 ZP_05364729.1 addiction module antitoxin, RelB/DinJ family
Campylobacter concisus pathogen 13826 YP_001466677.1 addiction module antitoxin
Campylobacter jejuni subsp. pathogen IA3902 ADC28395.1 prevent-host-death family protein
Campylobacter upsaliensis pathogen JV21 ZP_07894578.1* ChpA/MazF transcriptional modulator
Shigella flexneri 2a str. pathogen 301 NP_709188.1* PemK protein
Shigella flexneri 5 str. 8401 YP_690766.1 growth inhibitor, PemK-like, autoregulated
Cronobacter sakazakii pathogen ATCC BAA-894 YP_001436394.1 bifunctional antitoxin/transcriptional
repressor RelB
Lactobacillus coleohominis probiotic 101-4-CHN ZP_05553821.1* regulatory protein




probiotic ATCC 35646 ZP_00740711.1* MazF protein
KBAB4 YP_001643128.1 MazF protein
Bacillus weihenstephanensis AH1134 ZP_03233130.1 PemK family
Bacillus cereus
Coprobacillus sp. probiotic 29_1 ZP_08009764.1* PemK family transcriptional regulator
Enterococcus faecalis probiotic V583 NP_814592.1 PemK family transcriptional regulator
TX0102 EFQ11602.1* Toxin-antitoxin system, toxin compoment, MazF
TX2134 ZP_07557645.1* Toxin-antitoxin system, toxin compoment, MazF
HH22 ZP_03985009.1 PemK family transcriptional regulator
Lactobacillus plantarum probiotic WCFS1 NP_786238.1* cell growth regulatory protein
Lactobacillus rhamnosus probiotic LMS2-1 ZP_04441477.1* cell growth regulatory protein
Lc 705 YP_003175134.1 transcriptional modulator of MazE/toxin, MazF
Lactobacillus johnsonii probiotic ATCC 33200 ZP_04007131.1* PemK family growth inhibitor
Lactobacillus crispatus probiotics CTV-05 ZP_07789240.1* ppGpp-regulated growth inhibitor
Lactobacillus gasseri probiotic ATCC 33323 YP_815460.1* toxin-antitoxin system, toxin component,
MazF family224-1 ZP_06262236.1
MV-22 ZP_07711551.1
Lactobacillus casei probiotic BL23 YP_001986080.1 Cell growth regulatory protein
Lactobacillus amylovorus probiotic GRL1118 YP_005854914.1* transcriptional modulator of MazE/toxin MazF
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Table 2 The genetic characterization of the transcriptional modulator MazF, a chromosomal cell death factor from
potential probiotic strains and some major food-borne pathogens used in this study (Continued)
Vibrio cholerae probiotic 1587 ZP_01950611.1* transcriptional modulator of MazE/toxin, MazF
NCTC 8457 ZP_01969676.1
Pediococcus pentosaceus probiotic ATCC 25745 YP_805020.1* toxin-antitoxin addiction module toxin
component MazF (an endoRNAse)
Bacillus amyloliquefaciens probiotic Y2 YP_006327269.1* Endoribonuclease
Bacillus pumilus probiotic SAFR-032 YP_001485694.1* PemK family growth inhibitor
endoribonuclease EndoAATCC 7061 ZP_03054587.1
Lactobacillus sakei subsp. sakai probiotic Sakei 23K YP_396224.1 DNA-binding protein PemK family
Leuconostoc mesenteroides
subsp. mesenteroides
probiotic ATCC 8293 YP_819271.1* toxin-antitoxin addiction module toxin
component MazF
ATCC 19254 ZP_03913232.1 PemK family growth inhibitorLeuconostoc mesenteroides
subsp. cremoris




probiotic HN019 ZP_02964075.1* transcriptional modulator of
MazE/toxin, MazF
Bifidobacterium bifidum probiotic NCIMB 41171 ZP_03645723.1 RelB antitoxin
Bifidobacterium longum
subsp. longum
probiotic JDM301 YP_003660624.1* RelB antitoxin
DSM 20213 ZP_06596513.1 toxin-antitoxin system protein
Bifidobacterium breve
Bifidobacterium bifidum probiotic S17 YP_003938101.1 hypothetical protein with RelB
antitoxin domain
Lactobacillus casei Probiotic ATCC 334 YP_807723.1 toxin-antitoxin addiction module toxin
component MazF (an endoRNAse)
Lactobacillus casei Probiotic BL23 YP_001988635.1 Growth inhibitor
Lactobacillus paracasei subsp.
paracasei
Probiotic ATCC 25302 ZP_03963082.1* PemK family transcriptional regulator
Lactobacillus casei str. probiotic Zhang YP_003789562.1 toxin-antitoxin addiction module toxin
component MazF
Lachnospiraceae bacterium probiotic 3_1_57FAA_CT1 ZP_08609193.1* hypothetical protein HMPREF0994_05199
Leuconostoc citreum Probiotic KM20 YP_001727503.1* growth inhibitor
Lactobacillus reuteri probiotic DSM 20016 YP_001270863.1* transcriptional modulator of MazE/toxin, MazF
JCM 1112 YP_001841242.1 hypothetical protein LAR_0246
MM2-3 ZP_03847756.1 PemK family growth inhibitor
Streptococcus sp. oral
taxon 071 str.
probiotic 73H25AP ZP_07458552.1* ChpA/MazF transcriptional modulator
Bacillus selenitireducens probiotic MLS10 YP_003700699.1* transcriptional modulator of MazE/toxin, MazF
Bacillus halodurans probiotic C-125 NP_244588.1* ppGpp-regulated growth inhibitor (ChpA/MazF)
Enterococcus faecium probiotic DO ZP_05714797.1* PemK family protein
TX0133a04 ZP_07845579.1 toxin component, MazF family
TX0133C ZP_07850444.1 toxin component, MazF family
*: data are presented in Figure 1.
Yan et al. Cell & Bioscience 2012, 2:39 Page 7 of 13
http://www.cellandbioscience.com/content/2/1/39Figure 1. The principal basis behind the composition of
these probiotic cocktail strains is the assumption that a
combination of organisms might be more effective than
the application of a single strain, which potentially
could suppress many foodborne pathogens, such as the
E. coli and vibros in Group 1, several foodborne patho-
gens, such as Enterobacter, Klebsiella variicola, Salmon-
ella enterica, Shigella flexneri, Shigella dysenteriae,
Citrobacter rodentium, and Campylobacter upsaliensis,
(one of the most common Campylobacter strain found in
people with diarrhea in Group 2), Clostridium difficile,Listeria monocytogenes, and Listeria grayi, in Group 3 of
Figure 1. Table 1 shows an astonishing diversity in the
genomic GC-content and genome size among Lactobacil-
lus species and their diverse distribution in all groups
within Figure 1, which indicates a potential to further
identify other closely-related Lactobacillus species (not
listed in Table 1) into the three previously-described
groups. The hypothesis underlying our approach is that
probiotic strains found within the same group with food-
borne pathogens will have a reasonable degree of genetic
and molecular phylogenetic compatibility and could
Figure 1 Phylogenetic analyses of Enterobacteriaceae based on MazF (toxin), a growth inhibitor. The NCBI accession numbers are shown
after each taxon name.
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http://www.cellandbioscience.com/content/2/1/39bridge a relationship similar to a “symbiosis” of entities,
including exchanging toxin/antitoxin molecules among
the probiotic and pathogenic strains. Lactobacillus spe-
cies are known to produce antimicrobial substances, in-
cluding bacteriocins, lactic acid, and hydrogen peroxide.
The MazEF toxin component may provide a basis for
bacterial growth inhibition within the same group (Fig-
ure 1 and 2). Therefore, this toxin-antitoxin module may
have great potential to inhibit the growth of potentially-
pathogenic bacteria through a possible competitive ex-
clusion due to selective inhibition [46]. Figures 1 and 2
list all possible cocktails of these probiotic strains. In
reality, a foodborne outbreak is more likely to be asso-
ciated with one particular foodborne pathogen in par-
ticular foods. For example, there is a low incidence of
Campylobacter in ground beef and pork, while Cam-
pylobacter is the major foodborne pathogens associated
with poultry, therefore, a single food-borne pathogen
with the application of mixed probiotics will be consid-
ered initially.Molecular recombination techniques: construction of
genetically engineered synthetic probiotic strains
Figure 3 details an engineered probiotic strain bearing a
recombinant plasmid containing a stress-induced pro-
moter, followed by an in-frame gene fusion accom-
plished by fusing an appropriate signal peptide, a
functional cell death peptide/factor (CDF), an enteroki-
nase (EK) binding site, and a genetically-modified engi-
neered MazF gene, which will be constructed and
transformed into the probiotic bacteria. In this recom-
binant probiotic strain, environmental stress, relevant to
food environments will trigger gene expression of this
fusion protein under an environmental stress-inducible
promoter. The signal peptide directs the encoded fusion
protein to the extracellular space of the engineered pro-
biotic strains. The signal peptide depleted fusion pro-
teins will be cleaved by a biliary tract enterokinase
directly into the digestive system to release the
functionally-active CDF and MazF. This event will occur





Figure 2 ClustalW output (default settings) for the aligned amino acid sequences of MazF. The pdf images of the alignments were
generated using Geneious v5.5.7. Conserved amino acids are highlighted in colors; the numbers (1 to 39) in this Figure correspond to the taxon
names in Figure 1.
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http://www.cellandbioscience.com/content/2/1/39non-infectious biofilm-type aggregates, which may attach
with other bacteria, including foodborne pathogens, in
the urogenital and intestinal tracts [22]. These active
species-specific CDF and MazF proteins will bind and
pass through “unfriendly” bacterial cell surface barriers
into the cytoplasm. These processed CDFs and MazFFigure 3 A Schematic representation of the engineered, secreted CDF
storage. SP: promoter, CDF: cell death factor/peptide, EKB: enterokinase biproteins will selectively inactivate and/or inhibit proteins
involved in cell survival and induce the synthesis of more
cell death-related proteins with activity against food-
borne pathogens, eventually controlling, inhibiting, or in-
activating “unfriendly” cells. Although antitoxin MazE
could reverse the bacteriocidal effect of the overexpressedand MazF-mediated cell death during food processing and
nding site.
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http://www.cellandbioscience.com/content/2/1/39MazF, MazE cannot impede the downstream cascade
already initiated by MazF at early stages of the MazF-
mediated cascade [42].
The overall hypothesis for this experiment is graphic-
ally presented in Figure 3. The engineered MazF gene se-
quence will be designed based on the genomic sequences
of all publically-available foodborne pathogenic strains by
using reasoned random gene biosynthesis and/or genuine
gene reshuffling to rapidly combine functions and prop-
erties of parental genes for the development of improved
gene specificity and generality, molecular modeling (tran-
scription factor binding site identification, etc.), and sys-
tems biology technologies/tools.
Conclusions
Survival of foodborne pathogens in cultures or in animal
GI tracts may be very genus- or species-specific. Data
presented in this paper can be explored to develop ef-
fective intervention strategies applied directly during
food processing and preparation, as well as in the animal
feed supply, which may lead to an overall reduction in
use of antibiotic growth promoters (AGP) throughout
the world. Recent research in molecular biology and
genomics has provided potential applications of pro-
biotic strains as dietary supplements, which could re-
place AGP in animal diets or as biotherapeutic agents in
cases of antibiotic-associated diarrhea in travelers and in
childhood diarrhea and other bacterial gastrointestinal
illnesses. Experiments relating to this potential probiotic
application may reveal a further greater range of poten-
tial benefits. For many of these potential benefits, cur-
rent research is limited, and only preliminary results are
available. All effects can only be attributed to the indi-
vidual strain(s) tested. Testing of a specific supplement
may not be extrapolated to benefits from any other
strain of the same species, and testing results do not
imply that comparable benefits will be imparted from
other LAB (or other probiotics). In this study, we have
computationally explored several potential intervention
strategies to control foodborne pathogens, either by
using a cocktail of probiotic strains or an engineered
probiotic strain.
The inhibition of pathogens by probiotic strains is
mainly due to the production of antibacterial peptides
[67], the release of short-chain fatty acids, or reduction
of the pH within the lumen [68,69] by the production of
organic acids or by decreasing pathogen adherence to
intestinal epithelial cells [70]. Therefore, the benefits of
probiotics could be very strain- or species-specific, and
probiotic strains may rely on different mechanisms to
suppress growth, attachment, or other metabolic pro-
cesses, inherent to pathogenic bacteria. Moreover, the
optimal effects of probiotic strains may involve the sim-
ultaneous use of more than one strain. Our contentionin this paper is not experimental proof but, rather, a
clear scientifically-backed hypothesis in the form of a
detailed accompanying method that multi-probiotic
strain composites with diverse genetic backgrounds may
complement [71] one another as vectors of competitive
exclusion and, therefore, could maximize the potential
to inhibit an array of common foodborne pathogens [72]
in the gastrointestinal tract of humans or livestock, as
well as in foods and animal feed.
The use of probiotic bacteria with the ability to pro-
duce CDFs and engineered MazF to selectively inactivate
pathogens is a novel approach to controlling pathogens
in foods, and possibly treating human infections. A
number of studies suggest that this project could have
practical significance and be a potentially new approach
for the development of novel and cost-effective food
safety intervention technologies for the control of food-
borne pathogens and improving public health [73-75].
The approaches described above represent a first at-
tempt to describe a systematic approach or method to
test the hypothesis that “friendly” bacteria can be used
to inactivate or inhibit pathogens in food based on ex-
pression of MazF. There are many specific cell death fac-
tors that may be associated with bacterial programmed
cell death and multi-cellular behavior mechanisms in
foodborne pathogens. Through computational modeling,
remodeling, genetic recombination, or further gene re-
shuffling, and exploring experimental approaches, it may
be possible to evaluate and elucidate more effective
CDFs and MazF to be used for controlling foodborne
pathogens, which will ultimately result in a reduction in
the use of antimicrobial compounds in humans and ani-
mals, as well as during food processing and storage.
Materials and methods
Genomic sequences
All of the genome and gene sequences examined in this
study (Table 1 & 2) are available in GenBank (http://www.
ncbi.nlm.nih.gov/genbank/GenbankOverview.html).
Identification and analysis of bacterial toxin-antitoxin
modules, MazE/MazF
The prediction accuracy of the best chromosomal-
encoded MazF orthologs among relatively distinct gen-
ome strains is critical for the performance of molecular
phylogenetic analysis. We used a sequential BLAST
workflow based on pairwise comparison by applying
either an E. coli programmed cell death toxin MazF
(Genbank accession: ZP_06660634.1), an endoribonu-
clease MazF, a MazF protein from Vibrio cholerae
(ZP_01950611.1), or a PemK family transcriptional
regulator protein (ZP_05296226.1) from Listeria
monocytogenes to perform a BLASTP homology search
of these combined protein sequences with all 75
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http://www.cellandbioscience.com/content/2/1/39publically available foodborne pathogen and probiotic
strain genomic sequences (presented in Table 1) publi-
cally available databases such as NCBI and Uniprot data-
base (http://www.uniprot.org/). BLAST search results
were used to list MazF or MazF-like proteins from 75 dif-
ferent strains being represented as 39 different species
(Table 2).
Phylogenetic analysis and computational identification of
phylogenetic motifs of the MazF protein
In order to identify potential functional motifs of MazF
proteins, phylogentic analyses of MazF proteins were
conducted by applying the embedded multiple sequence
alignment ClustalW program in the Geneious software
package v 5.5.7 [76,77] with the Neighbor Joining method.
ClustalW output for the aligned amino acid sequences
and the pdf images of the alignments were generated
using the Geneious software package v 5.5.7.
Competing interests
Mention of trade names or commercial products in this publication is solely
for the purpose of providing specific information and does not imply
recommendation or endorsement by the U.S. Department of Agriculture.
USDA is an equal opportunity provider and employer.
Authors’ contributions
XY conceived the study. XY and JH performed the bioinformatics study and
XY wrote the paper. All authors read and approved the manuscript.
Acknowledgements
We express our appreciation to Dr. James Smith for his critical review of the
manuscript. The mention of trade names or commercial products is solely
for the purpose of providing specific information and does not imply
recommendation or endorsement by the U.S. Department of Agriculture.
Author details
1Eastern Regional Research Center, Agricultural Research Service, U.S.
Department of Agriculture, 600 E. Mermaid Lane, Wyndmoor, PA 19038, USA.
2Department of Mathematics and Computer Science, Franklin & Marshall
College, P.O. Box 3003, Lancaster, PA 17604, USA.
Received: 14 May 2012 Accepted: 10 October 2012
Published: 27 November 2012
References
1. World Health Organization (WHO), Food and Agriculture Organization of
the United Nations, and the World Organization for Animal Health: Expert
workshop on non-human antimicrobial usage and antimicrobial resistance.
Geneva; 2003. http://www.who.int/foodsafety/publications/micro/en/amr.
pdf.
2. CDC: Are antibacterial-containing products (soaps, household cleaners, etc.)
better for preventing the spread of infection? Does their use add to the
problem of resistance? Atlanta: Antibiotic Resistance Questions & Answers,
Centers for Disease Control and Prevention; 2009.
3. Ferber D: Antibiotic resistance. Livestock feed ban preserves drugs’ power.
Science 2002, 295:27–28.
4. Goossens H, Ferech M, Vander Stichele R, Elseviers M: Outpatient antibiotic
use in Europe and association with resistance: a cross-national database
study. Lancet 2005, 365:579–587.
5. Mathew AG, Cissell R, Liamthong S: Antibiotic resistance in bacteria
associated with food animals: a United States perspective of livestock
production. Foodborne Pathog Dis 2007, 4:115–133.
6. WHO: Use of antimicrobials outside human medicine and resultant
antimicrobial resistance in humans [R].: World Health Organization; 2002.
http://www.who.int/mediacentre/factsheets/fs268/en/index.html.7. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI:
Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005,
102:11070–11075.
8. Possemiers S, Grootaert C, Vermeiren J, Gross G, Marzorati M, Verstraete W,
Van de Wiele T: The intestinal environment in health and disease - recent
insights on the potential of intestinal bacteria to influence human
health. Curr Pharm Des 2009, 15:2051–2065.
9. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S,
Collini S, Pieraccini G, Lionetti P: Impact of diet in shaping gut microbiota
revealed by a comparative study in children from Europe and rural
Africa. Proc Natl Acad Sci U S A 2010, 107:14691–14696.
10. Qu A, Brulc JM, Wilson MK, Law BF, Theoret JR, Joens LA, Konkel ME, Angly
F, Dinsdale EA, Edwards RA, Nelson KE, White BA: Comparative
metagenomics reveals host specific metavirulomes and horizontal gene
transfer elements in the chicken cecum microbiome. PLoS One 2008,
3:e2945.
11. Torok VA, Ophel-Keller K, Loo M, Hughes RJ: Application of methods for
identifying broiler chicken gut bacterial species linked with increased
energy metabolism. Appl Environ Microbiol 2008, 74:783–791.
12. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE,
Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC,
Knight R, Gordon JI: A core gut microbiome in obese and lean twins.
Nature 2009, 457:480–484.
13. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E,
Munoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the
human intestinal microbiota phylogenetic core. Environ Microbiol 2009,
11:2574–2584.
14. Cabana MD, Shane AL, Chao C, Oliva-Hemker M: Probiotics in primary care
pediatrics. Clin Pediatr (Phila) 2006, 45:405–410.
15. Cadieux P, Wind A, Sommer P, Schaefer L, Crowley K, Britton RA, Reid G:
Evaluation of reuterin production in urogenital probiotic Lactobacillus
reuteri RC-14. Appl Environ Microbiol 2008, 74:4645–4649.
16. Cadieux PA, Burton J, Devillard E, Reid G: Lactobacillus by-products inhibit
the growth and virulence of uropathogenic Escherichia coli. J Physiol
Pharmacol 2009, 60(Suppl 6):13–18.
17. Canny GO, McCormick BA: Bacteria in the intestine, helpful residents or
enemies from within? Infect Immun 2008, 76:3360–3373.
18. Gillor O, Etzion A, Riley MA: The dual role of bacteriocins as anti- and
probiotics. Appl Microbiol Biotechnol 2008, 81:591–606.
19. Lidbeck A, Edlund C, Gustafsson JA, Kager L, Nord CE: Impact of
Lactobacillus acidophilus on the normal intestinal microflora
after administration of two antimicrobial agents. Infection 1988,
16:329–336.
20. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC: Mechanisms of action of
probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300–310.
21. Reid G, Bruce AW: Urogenital infections in women: can probiotics help?
Postgrad Med J 2003, 79:428–432.
22. Reid G, Jass J, Sebulsky MT, McCormick JK: Potential uses of probiotics in
clinical practice. Clin Microbiol Rev 2003, 16:658–672.
23. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R,
Roberfroid M, Rowland I, Cherbut C, Klaenhammer TR: New scientific
paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003,
37:105–118.
24. Grady R, Hayes F: Axe-Txe, a broad-spectrum proteic toxin-antitoxin
system specified by a multidrug-resistant, clinical isolate of Enterococcus
faecium. Mol Microbiol 2003, 47:1419–1432.
25. Masuda Y, Miyakawa K, Nishimura Y, Ohtsubo E: chpA and chpB, Escherichia
coli chromosomal homologs of the pem locus responsible for stable
maintenance of plasmid R100. J Bacteriol 1993, 175:6850–6856.
26. Masuda Y, Ohtsubo E: Mapping and disruption of the chpB locus in
Escherichia coli. J Bacteriol 1994, 176:5861–5863.
27. Gerdes K, Christensen SK, Lobner-Olesen A: Prokaryotic toxin-antitoxin
stress response loci. Nat Rev Microbiol 2005, 3:371–382.
28. Kolodkin-Gal I, Verdiger R, Shlosberg-Fedida A, Engelberg-Kulka H: A
differential effect of E. coli toxin-antitoxin systems on cell death in liquid
media and biofilm formation. PLoS One 2009, 4:e6785.
29. Mittenhuber G: Occurrence of mazEF-like antitoxin/toxin systems in
bacteria. J Mol Microbiol Biotechnol 1999, 1:295–302.
30. Sat B, Hazan R, Fisher T, Khaner H, Glaser G, Engelberg-Kulka H:
Programmed cell death in Escherichia coli: some antibiotics can trigger
mazEF lethality. J Bacteriol 2001, 183:2041–2045.
Yan et al. Cell & Bioscience 2012, 2:39 Page 12 of 13
http://www.cellandbioscience.com/content/2/1/3931. Johnson EP, Strom AR, Helinski DR: Plasmid RK2 toxin protein ParE:
purification and interaction with the ParD antitoxin protein. J Bacteriol
1996, 178:1420–1429.
32. Santos-Sierra S, Pardo-Abarrio C, Giraldo R, Diaz-Orejas R: Genetic
identification of two functional regions in the antitoxin of the parD killer
system of plasmid R1. FEMS Microbiol Lett 2002, 206:115–119.
33. Sobecky PA, Easter CL, Bear PD, Helinski DR: Characterization of the stable
maintenance properties of the par region of broad-host-range plasmid
RK2. J Bacteriol 1996, 178:2086–2093.
34. Zhang Y, Zhu L, Zhang J, Inouye M: Characterization of ChpBK, an mRNA
interferase from Escherichia coli. J Biol Chem 2005, 280:26080–26088.
35. Bech FW, Jorgensen ST, Diderichsen B, Karlstrom OH: Sequence of the relB
transcription unit from Escherichia coli and identification of the relB
gene. EMBO J 1985, 4:1059–1066.
36. Gotfredsen M, Gerdes K: The Escherichia coli relBE genes belong to a new
toxin-antitoxin gene family. Mol Microbiol 1998, 29:1065–1076.
37. Gunn JS, Miller SI: PhoP-PhoQ activates transcription of pmrAB,
encoding a two-component regulatory system involved in Salmonella
typhimurium antimicrobial peptide resistance. J Bacteriol 1996,
178:6857–6864.
38. Lippa AM, Goulian M: Feedback inhibition in the PhoQ/PhoP signaling
system by a membrane peptide. PLoS Genet 2009, 5:e1000788.
39. Monsieurs P, De Keersmaecker S, Navarre WW, Bader MW, De Smet F,
McClelland M, Fang FC, De Moor B, Vanderleyden J, Marchal K: Comparison
of the PhoPQ regulon in Escherichia coli and Salmonella typhimurium.
J Mol Evol 2005, 60:462–474.
40. Zwir I, Shin D, Kato A, Nishino K, Latifi T, Solomon F, Hare JM, Huang H,
Groisman EA: Dissecting the PhoP regulatory network of Escherichia coli
and Salmonella enterica. Proc Natl Acad Sci U S A 2005, 102:2862–2867.
41. Amitai S, Kolodkin-Gal I, Hananya-Meltabashi M, Sacher A, Engelberg-Kulka
H: Escherichia coli MazF leads to the simultaneous selective synthesis of
both “death proteins” and “survival proteins”. PLoS Genet 2009, 5(3):
e1000390. doi:10.1371/journal.pgen.1000390.
42. Amitai S, Yassin Y, Engelberg-Kulka H: MazF-mediated cell death in
Escherichia coli: a point of no return. J Bacteriol 2004, 186:8295–8300.
43. Park JH, Yamaguchi Y, Inouye M: Intramolecular regulation of the
sequence-specific mRNA interferase activity of MazF fused to a MazE
fragment with a linker cleavable by specific proteases. Appl Environ
Microbiol 2012, 78(11):3794–3799.
44. Belitsky M, Avshalom H, Erental A, Yelin I, Kumar S, London N, Sperber M,
Schueler-Furman O, Engelberg-Kulka H: The Escherichia coli extracellular
death factor EDF induces the endoribonucleolytic activities of the toxins
MazF and ChpBK. Mol Cell 2012, 41(6):625–635.
45. Engelberg-Kulka H, Sat B, Reches M, Amitai S, Hazan R: Bacterial
programmed cell death systems as targets for antibiotics. Trends
Microbiol 2004, 12(2):66–71.
46. Rothenbacher FP, Suzuki M, Hurley JM, Montville TJ, Kirn TJ, Ouyang M,
Woychik NA: Clostridium difficile MazF toxin exhibits selective, not
global, mRNA cleavage. J Bacteriol 2012, 194(13):3464–3474.
47. Juneja VK, Dwivedi HP, Yan X: Novel natural food antimicrobials. Annu Rev
Food Sci Technol 2012, 3:381–403.
48. de Vuyst L, Vandamme E: Antimicrobial potential of lactic acid bacteria.
In Bacteriocins of Lactic Acid Bacteria. Microbiology, Genetics and Applications.
Edited by de Vuyst L, Vandamme EJ. London: Blackie Acad Prof;
1994:91–142.
49. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T: Lactobacillus
reuteri as a therapeutic agent in acute diarrhea in young children.
J Pediatr Gastroenterol Nutr 1997, 24:399–404.
50. Williams MD, Ha CY, Ciorba MA: Probiotics as therapy in gastroenterology:
a study of physician opinions and recommendations. J Clin Gastroenterol
2010, 44:631–636.
51. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S: Survival
of Lactobacillus species (strain GG) in human gastrointestinal tract.
Dig Dis Sci 1992, 37:121–128.
52. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J: Clostridium difficile
pilot study: effects of probiotic supplementation on the incidence of
C. difficile diarrhoea. Int Microbiol 2004, 7:59–62.
53. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ:
Lactobacillus GG in the prevention of antibiotic-associated diarrhea in
children. J Pediatr 1999, 135:564–568.54. Vanderhoof JA, Young RJ: Current and potential uses of probiotics.
Ann Allergy Asthma Immunol 2004, 93:S33–S37.
55. Arber W: Genetic variation: molecular mechanisms and impact on
microbial evolution. FEMS Microbiol Rev 2000, 24:1–7.
56. Saito H, Kashida S, Inoue T, Shiba K: The role of peptide motifs in the
evolution of a protein network. Nucleic Acids Res 2007, 35:6357–6366.
57. Hadorn B, Steiner N, Sumida C, Peters TJ: Intestinal enterokinase.
Mechanisms of tts “secretion” into the lumen of the small intestine.
Lancet 1971, 1:165–166.
58. Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE: Enterokinase, the
initiator of intestinal digestion, is a mosaic protease composed of a
distinctive assortment of domains. Proc Natl Acad Sci U S A 1994,
91:7588–7592.
59. Song HW, Choi SI, Seong BL: Engineered recombinant enteropeptidase
catalytic subunit: effect of N-terminal modification. Arch Biochem Biophys
2002, 400:1–6.
60. Zhang Y, Vankemmelbeke MN, Holland LE, Walker DC, James R, Penfold CN:
Investigating early events in receptor binding and translocation of
colicin E9 using synchronized cell killing and proteolytic cleavage.
J Bacteriol 2008, 190:4342–4350.
61. Hildebrand F, Meyer A, Eyre-Walker A: Evidence of Selection upon
Genomic GC-Content in Bacteria. PLoS Genet 2010, 6(9):e1001107.
doi:10.1371/journal.pgen.1001107.
62. Bentley SD, Parkhill J: Comparative genomic structure of prokaryotes.
Annu Rev Genet 2004, 38:771–792.
63. Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, Bingen E,
Bonacorsi S, Bouchier C, Bouvet O, Calteau A, Chiapello H, Clermont O,
Cruveiller S, Danchin A, Diard M, Dossat C, Karoui ME, Frapy E, Garry L,
Ghigo JM, Gilles AM, Johnson J, Le Bouguenec C, Lescat M, Mangenot S,
Martinez-Jehanne V, Matic I, Nassif X, Oztas S, et al: Organised genome
dynamics in the Escherichia coli species results in highly diverse adaptive
paths. PLoS Genet 2009, 5:e1000344.
64. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A,
Albano F, Passariello A, De Marco G, Manguso F, Guarino A: Probiotics for
treatment of acute diarrhoea in children: randomised clinical trial of five
different preparations. BMJ 2007, 335:340.
65. Weizman Z, Asli G, Alsheikh A: Effect of a probiotic infant formula on
infections in child care centers: comparison of two probiotic agents.
Pediatrics 2005, 115:5–9.
66. Quigley EMM, Sanders ME: Probiotic foods for gastrointestinal health.
Gastroenterology & Endoscopy News Special Edition 2009,
7:27–33.
67. Corr SC, Gahan CG, Hill C: Impact of selected Lactobacillus and
Bifidobacterium species on Listeria monocytogenes infection and the
mucosal immune response. FEMS Immunol Med Microbiol 2007,
50:380–388.
68. Marteau P, Seksik P: Tolerance of probiotics and prebiotics. J Clin Gastroenterol
2004, 38:S67–S69.
69. Marteau P, Seksik P, Lepage P, Dore J: Cellular and physiological effects of
probiotics and prebiotics. Mini Rev Med Chem 2004,
4:889–896.
70. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA: Probiotics
inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal
mucin gene expression. Am J Physiol 1999, 276:G941–G950.
71. Klaenhammer TR, Kullen MJ: Selection and design of probiotics. Int J Food
Microbiol 1999, 50:45–57.
72. Cursino L, Smajs D, Smarda J, Nardi RM, Nicoli JR, Chartone-Souza E,
Nascimento AM: Exoproducts of the Escherichia coli strain H22 inhibiting
some enteric pathogens both in vitro and in vivo. J Appl Microbiol 2006,
100:821–829.
73. Iacono A, Raso GM, Canani RB, Calignano A, Meli R: Probiotics as an
emerging therapeutic strategy to treat NAFLD: focus on molecular and
biochemical mechanisms. J Nutr Biochem 2010, 22:699–711.
74. Lu TK, Collins JJ: Engineered bacteriophage targeting gene networks as
adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 2009,
106:4629–4634.
75. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG,
Norris JS: Use of genetically engineered phage to deliver antimicrobial
agents to bacteria: an alternative therapy for treatment of bacterial
infections. Antimicrob Agents Chemother 2003, 47:1301–1307.
Yan et al. Cell & Bioscience 2012, 2:39 Page 13 of 13
http://www.cellandbioscience.com/content/2/1/3976. Drummond A, Ashton B, Buxton S: Geneious v5.4; 2011. http://www.
geneious.com.
77. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S,
Cooper A, Markowitz S, Duran C, et al: Geneious Basic: an integrated and
extendable desktop software platform for the organization and analysis
of sequence data. Bioinformatics 2012, 28(12):1647–1649.
doi:10.1186/2045-3701-2-39
Cite this article as: Yan et al.: Phylogenetic identification of bacterial
MazF toxin protein motifs among probiotic strains and foodborne
pathogens and potential implications of engineered probiotic
intervention in food. Cell & Bioscience 2012 2:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
